Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7284755 alone or with atezolizumab in advanced or metastatic solid tumors
NL-OMON59859Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of eciskafusp alfa and atezolizumab, sponsored by Roche. Started Jun 2020; status: completed.
02
Drugs
eciskafusp alfaatezolizumab
Beyond the preview
Go deeper on NL-OMON59859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59859.